Gastrodyne is a swallowable, biodegradable smart capsule that finds inflamed GI tissue and delivers therapy exactly at the site of disease; improving efficacy while reducing systemic side effects and patient burden. The capsule combines on‑board sensing (pH/microbiome cues), imaging, and controlled actuation to release drug locally in the small bowel or colon. We have 1×2.5 cm prototypes with a working camera and are assembling the MVP with safe, low‑power actuation and multi‑trigger localization. In primary research with 10 gastroenterologists and ~150 patients, both groups highlighted the need for a non‑invasive, targeted alternative and expressed interest in pilots. Our market analysis indicates a $50B+ total addressable market across IBD, CRC and targeted GI drug delivery/diagnostics.
Stage 1: Interaction Award ($5,000): This award focuses on the person, and is granted to FEAS students who have a new idea that does not exist in the market and solves a problem.
Stage 2: Development Award ($8,000): This award is granted to FEAS students who have completed formal market research and have proven a demand for their idea in the market.
Stage 3: Market Readiness Award ($25,000): This award is granted to FEAS students who have completed formal business plans and/or alpha or beta prototype(s).
Feel free to reach out for collaborations or research discussions.
Email